Everolimus- and temsirolimus-associated enteritis: Report of three cases

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages

  Parithivel, Kavitha ^a   Ramaiya, Nikhil ^a   Jagannathan, Jyothi Priya ^a   O'Regan, Kevin ^a   Krajewski, Katherine ^a   Fisher, David ^a   Choueiri, Toni K ^a   Jacobsen, Eric ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; PREDNISONE; RITUXIMAB; SUNITINIB; TEMSIROLIMUS; VINCRISTINE;

ABDOMINAL PAIN; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CHILL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; ENTERITIS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79955795634     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.5984     Document Type: Article

References (16)

1. LoPiccolo J, Blumenthal G, Bernstein W, et al: Targeting the P13K/Akt/ mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat 11:32-50, 2008
2. Wanner K, Hipp S, Oelsner M, et al: Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475-484, 2006 (Pubitemid 44141713)
3. Panwalkar A, Verstovsek S, Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100:657-666, 2004 (Pubitemid 38176841)
4. Zhou H, Luo Y, Huang S: Updates of mTOR inhibitors. Anticancer Agents Med Chem 10:571-581, 2010
5. Vickers M, Choueiri T, Rogers M, et al: Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factortargeted therapy. Urology 76:430-434, 2010
6. Hainsworth J, Spigel D, Burris H III, et al: Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131-2136, 2010
7. Punt CJ, Boni J, Bruntsch U, et al: Phase 1 and pharmacokinetic study of CC1-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937, 2003 (Pubitemid 36827210)
8. Hudes G, Carducci M, Tomcat P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
9. Rodriguez-Pascual J, Cheng E, Maroto P, et al: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21:478-486, 2010
10. Otto T, Eimer C, Gerullis H: Temsirolimus in renal cell carcinoma. Transplant Proc 40:S36-S39, 2008
11. Saif MW, Elfiky A, Salem RR: Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860-1869, 2007
12. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-473, 2005
13. Keating GM: Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445-1476, 2010
14. Coiffier B: Rituximab therapy in malignant lymphoma. Oncogene 26:3603-3613, 2007
15. Ardelean DS, Gonska T, Wires S, et al: Severe ulcerative colitis after rituximab therapy. Pediatrics 26:243-246, 2010
16. Rhoads J, Niu X, Odle J, et al: Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiology 291:G510-G517, 2006 (Pubitemid 44330172)